These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
627 related articles for article (PubMed ID: 26980575)
1. A new paradigm of genetic testing for hereditary breast/ovarian cancers. Kwong A; Chen JW; Shin VY Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575 [TBL] [Abstract][Full Text] [Related]
2. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215 [TBL] [Abstract][Full Text] [Related]
3. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709 [TBL] [Abstract][Full Text] [Related]
5. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021 [TBL] [Abstract][Full Text] [Related]
6. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518 [TBL] [Abstract][Full Text] [Related]
7. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
8. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
10. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778 [TBL] [Abstract][Full Text] [Related]
11. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer. Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076 [TBL] [Abstract][Full Text] [Related]
12. Familial breast and ovarian cancers. Arai M; Utsunomiya J; Miki Y Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703 [TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
14. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933 [TBL] [Abstract][Full Text] [Related]
16. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591 [TBL] [Abstract][Full Text] [Related]
17. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery]. Arai M; Iwase T; Takazawa Y; Takeshima N Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434 [TBL] [Abstract][Full Text] [Related]
18. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
19. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844 [TBL] [Abstract][Full Text] [Related]